Skip to main content

Clinical Practice Guideline Updated for Migraine, Tension-Type Headache

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 29, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Oct. 29, 2024 -- In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Oct. 29 in the Annals of Internal Medicine, updated recommendations are presented for the management of migraine and tension-type headache (TTH).

Noting that the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense CPG for the management of headache was revised in 2023 in accordance with rapidly expanding and evolving evidence, Jason J. Sico, M.D., from the VA Connecticut Healthcare System in West Haven, and colleagues reviewed the recommendations relevant to primary care clinicians for treatment and prevention of migraine and TTH. Twelve key questions were developed, which guided a systematic search using predefined inclusion and exclusion criteria.

Fifty-two recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions for selected primary and secondary headache disorders were included in the revised CPG. Newer calcitonin gene-related peptide (CGRP) inhibitors (gepants) are options for acute migraine treatment in addition to triptans and aspirin-acetaminophen-caffeine. Angiotensin-receptor blockers, lisinopril, magnesium, topiramate, valproate, memantine, the newer CGRP monoclonal antibodies, and atogepant can be used to prevent episodic migraine. For prevention of chronic migraine, but not episodic migraine, abobotulinumtoxinA can be used. Gabapentin is not recommended for episodic migraine prevention. Treatment of TTH can include ibuprofen (400 mg) and acetaminophen (1,000 mg); for preventing chronic TTH, amitriptyline can be used. Management of TTH and migraines can also include physical therapy or aerobic exercise.

"Clinicians should work with their patients in crafting treatment plans that account for headache type or types, comorbid conditions, and values and preferences," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

No Increase Seen in Neurodevelopmental Disorders With Prenatal Triptan Use

WEDNESDAY, May 21, 2025 -- Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do...

Ubrogepant During Prodromal Phase of Migraine Eases Symptoms

TUESDAY, May 13, 2025 -- Ubrogepant during the prodromal phase of migraine may alleviate common prodromal symptoms, according to a study published online May 12 in Nature...

Study Sheds Light on Role of Risk Factors in Young-Onset Cryptogenic Ischemic Stroke

THURSDAY, April 17, 2025 -- Traditional risk factors contribute to young-onset cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), while nontraditional risk...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.